Tue, Sep 21, 2021
Mantra Bio today announced the appointment of Maria Fuentes, Ph.D. as the company’s Chief Scientific Officer. Dr. Fuentes joins Mantra Bio after holding research leadership positions at Roche, Bristol-Myers Squibb, and most recently Blade Therapeutics, where she was Executive Vice President of Research.
Tue, Aug 4, 2020
"We are excited to announce that 8VC and Viking Global are co-leading a $25M Series A investment into Mantra Bio to help them build out their exosome therapeutics platform. 8VC has backed Mantra since its pre-seed stage in 2017 when they were starting at the Illumina accelerator. The team has shown amazing progress and exciting results around cell-specific targeted exosomes. We are excited to partner with them as they expand their plans to engineer, manufacture, and deliver novel treatments to patients in dire need."
Mon, Jul 31, 2017
Mantra Bio joins the Illumina Accelerator. Mantra is working on exosome biology. Exosomes are vesicles released by all cells and found in almost all body fluids. They were commonly viewed as acting like garbage containers for cells, but recently they have been found to be involved in communication and delivery functions in the cells. Other companies working on this included Codiak Biosciences, EvOx Therapeutics, ReNeuron and Capricor.